Introduction {#s1}
============

Brain function relies on the efficient processing of sensory information, which in turn requires the proper formation and interaction of multiple sensory maps of the world. The superior colliculus (SC) of the midbrain is a major hub for sensory processing, as it receives organized inputs from visual, auditory, and somatosensory modalities ([@bib26]). The SC is a laminated structure controlling visuo-spatial orientation and attention ([@bib26]; [@bib21]). As such, defective visual processing in the SC has been associated with psychiatric conditions ([@bib25]). Visual information reaches the superficial layers of the SC, which are innervated both by retinal ganglion cells (RGCs - the retino-collicular projection) and by layer V neurons of the primary visual cortex V1 (the cortico-collicular projection). During development in the mouse, the retino-collicular map forms during the first post-natal week, and is followed by the cortico-collicular map, which develops between P6 and P12 ([@bib39]). These visuotopic maps must be aligned to ensure efficient modulation of the SC's retinal response by V1 inputs ([@bib48]; [@bib23]). It has been suggested that the formation of the visuotopy is a stochastic process instructed by a balanced contribution of molecular cues and correlated neuronal activity ([@bib8]; [@bib42]; [@bib41]; [@bib39]; [@bib1]; [@bib29]). However the basic principles and underlying molecular mechanisms governing the alignment of converging maps have not been fully described.

Potential candidates are gradients of Eph receptor tyrosine kinases (EPHs) and their membrane-bound ligands, the ephrins (EFNs), already known to control retino-collicular map formation. In the mouse, EPHA4/A5/A6 receptors are present on projecting RGCs in a low-nasal to high-temporal gradient. RGC axons are repelled when their EPHAs contact and are activated by collicular EFNA2/A3/A5, expressed in a low-rostral to high-caudal gradient in the SC ([@bib22]; [@bib4]). Counter-gradients of ligands (EFNA2/A3/A5) and receptors (EPHA3/A4/A7) are also present in the RGCs and the SC respectively, but their role remains controversial ([@bib15]; [@bib38]; [@bib37]; [@bib43]). In V1, gradients of EPHA4/A7, running from high-lateral to low-medial have also been observed, and evidence from genetic analyses suggests their involvement in the development of cortico-collicular projections ([@bib5]; [@bib44]). Moreover, the formation of the cortico-collicular map requires retinal input ([@bib19]; [@bib39]), but again, the underlying molecular mechanisms remain elusive.

The complex expression patterns of *Epha/Efna* gradients in both projecting and target structures require the development of incisive in vivo approaches to address, in a selective and quantitative manner, the function of these gradients in specific neuronal projections. Here, we analyzed the role of retinal *Efna* gradients in visuotopic map formation in the SC. We generated a unique mouse model in which EFNA3 is ectopically expressed only in *Isl2*(+) RGCs, therefore quantitatively disrupting the EFNA gradients exclusively in the retina without affecting *Ephas/Efnas* expression in other visually-related structures. Surprisingly, *Isl2-ires-Efna3* knock-in mice (referred as Efna3 KI) exhibited normal retino-collicular/geniculate maps and normal ipsi/contra-lateral projections. In marked contrast, the formation of the cortico-collicular map was severely disrupted, leading to a mix of single and duplicated projections and generating a mismatch with the retino-collicular map. The causal role of EFNA3 ectopic expression was further confirmed when in vivo inactivation by co-expressed EPHA3 receptor in the same *Isl2*(+) RGCs restored a wild-type map. Theoretical modelling recapitulated our experimental observations in normal and aberrant conditions induced by EFNA3 ectopic expression, therefore validating the basic principle and mechanism of map alignment. This mechanism suggests that a leading sensory map carries positional information cues for further sensory projections, within the same modality, to align and adjust.

Results {#s2}
=======

Knock-in mice for *Efna3* ectopic expression in *Isl2*(+) RGCs show normal retino-collicular and retino-geniculate projections {#s2-1}
------------------------------------------------------------------------------------------------------------------------------

To test the role of retinal EFNA ligands in visuotopic map formation, we generated knock-in mice in which a full length *Efna3* cDNA was inserted, flanked by an internal ribosome entry site (ires), into the 3\'-UTR region of the *Islet-2* (*Isl2*) gene ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), similar to a previous approach ([@bib3]). Immunohistochemical staining confirmed ectopic expression of EFNA3 in somata and proximal axons of *Isl2*(+) RGCs in postnatal day 1 (P1) and P8 *Efna3* homozygous knock-in (Efna3KI/KI) mice compared to wild-type (WT) littermates ([Figure 1A--F](#fig1){ref-type="fig"}) without affecting *Isl2* expression at P1 ([Figure 1G,H](#fig1){ref-type="fig"}). Efna3KI/KI mice present two intermixed sub-populations of RGCs: *Isl2*(−) cells, expressing wild-type levels of *Efna3*, and *Isl2*(+) cells expressing additional *Efna3* ([Figure 1E--F,I--N](#fig1){ref-type="fig"}). EFNA3 is observed on RGC axons in vitro ([Figure 1O,Q'](#fig1){ref-type="fig"}). Ectopic expression of EFNA in *Isl2*(+) RGCs did not induce perceptible changes in synaptic layers or retinal organization ([Figure 2A,B](#fig2){ref-type="fig"}). Quantitative transcript (mRNA) measurement on RGC cell bodies, performed and standardized as described previously ([@bib33]; [@bib9]) confirmed a two-fold increase of *Efna3* mRNA and normal levels of *Efna2/a5* mRNA in nasal, central and temporal Efna3KI/KI mutant retinas when compared to WT littermates ([Figure 2C](#fig2){ref-type="fig"}). Together, these data confirm a two-fold ectopic expression of *Efna3* in *Isl2*(+) Efna3KI/KI RGCs, which generates an oscillating high-nasal to low-temporal gradient in *Efna*s expression in the Efna3 KI mouse, very similar to the oscillating *Ephas* gradient we previously described for *Isl2-Epha3* knock-in mice ([@bib33]).10.7554/eLife.20470.002Figure 1.Validation of the Efna3 KI model I.(**A--F**) Immunochemical staining using anti-EFNA3 (LS-C6547, LS-Bio) in P1 (**A, B**) and P8 (**C**) WT (n = 3 animals) and P1 (**D, E**) and P8 (**F**) Efna3KI/KI (n = 5 animals) RGCs. In (**E, F**) arrows indicate EFNA3 WT expression level in RGCs, arrowheads indicate putative ectopic (knock-in) EFNA3 expression in RGCs. The asterisk highlights strong EFNA3 labelling in the RGC fiber layer. Scale bars represent 200 μm (**A, D**), 20 μm (**B--F**). (**G--H**) Immunostaining of ISL2 in P1 WT (n = 3 animals) (**G**) and Efna3KI/KI (n = 5 animals) (**H**) RGCs in the ganglion cell layer. Arrowheads indicate ISL2(+) RGCs. Scale bars represent 20 μm. (**I--N**) Immunostaining of ISL2 (**I, L**), EFNA3 (LS-C6547, LS-Bio) (**J, M**) and merged (**K, N**) in P1 and P7 Efna3KI/KI (n = 5 animals) RGCs. Arrowheads indicate ISL2(+) RGCs with high EFNA3. Arrows indicate ISL2(-) RGCs with wild-type EFNA3 level. Scale bars represent 10 µm. (**O, Q'**) EFNA3 (LS-C6547, LS-Bio) (**O, Q, Q'**) and axonal marker TAU (**P, Q, Q'**) co-immunostaining on P6 RGC in culture (DIV 5) (n = 3 animals). (**Q'**) shows an EFNA3/TAU co-labelled RGC axon at higher magnification. Scale bars represent 10 µm. GCL, ganglion cell layer; RGC, retinal ganglion cell; DIV, days in vitro; WT, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.002](10.7554/eLife.20470.002)10.7554/eLife.20470.003Figure 1---figure supplement 1.Scheme of the knock-in strategy generating the *Isl2-ires-Efna3* mutant mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.003](10.7554/eLife.20470.003)10.7554/eLife.20470.004Figure 2.Validation of the Efna3 KI model II.(**A, B**) Synaptophysin (red) and DAPI (blue) staining in P34 WT (n = 4 animals) (**A**) and Efna3KI/KI (n = 4 animals) (**B**) retinas. Scale bars represent 50 µm. (**C**) *Efna* mRNAs relative to nasal WT quantified in acutely isolated RGCs from nasal (**N**), central (**C**) and temporal (**T**) retinas and normalized against *Gapdh* and *Hprt* in P3 WT and Efna3KI/KI (WT, n = 6 animals/12 retinas; Efna3KI/KI, n = 8 animals/16 retinas, variables are normally distributed, two-way ANOVA: *Efna2* genotype F~11,3~ = 1.79, p = 0.11; *Efna5* genotype F~11,3~ = 2.08, p = 0.07; *Efna3* genotype F~11,3~ = 8.11, \*\*\*p\<0.001). WT, wild-type; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; OS, outer and inner segments; RGCs, retinal ganglion cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.004](10.7554/eLife.20470.004)

To study retino-collicular map formation, we performed focal anterograde DiI labelling in the retina of P7 mice and analyzed the termination zones (TZs) in the SC at P8, as described previously ([@bib3]; [@bib33]; [@bib2]). For quantitative analysis, we measured the locations of the termination zones (TZs) along the rostral-caudal axis of the SC and the location of the focal DiI injections along the nasal-temporal axis of the retina ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Plotting these values in Cartesian coordinates, as described previously ([@bib3]; [@bib33]; [@bib2]), revealed normal linear retino-collicular maps in Efna3KI/KI and Efna3KI/+ mice, equivalent to those of WT littermates ([Figure 3A](#fig3){ref-type="fig"}). Detailed analysis showed that the size and the layering of the retinal TZs are similar between Efna3KI/KI and WT littermates ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Retrograde labelling confirmed that axons from both *Isl2*(−) and *Isl2*(+) RGCs project to the SC ([Figure 3B--G](#fig3){ref-type="fig"}). Anterograde focal injections show normal retino-geniculate mapping ([Figure 3H--K](#fig3){ref-type="fig"}) and labelling by full-eye fills showed normal retino-collicular/geniculate eye-specific segregation ([Figure 3L--Q](#fig3){ref-type="fig"}) in Efna3KI/KI similarly to WT littermates. These results demonstrated that a two-fold increase of ectopic retinal *Efna3* expression in *Isl2*(+) RGCs does not disturb the formation of the retino-collicular/geniculate mapping nor eye-specific segregation.10.7554/eLife.20470.005Figure 3.Retinal anterograde mapping and retrograde DiI labelling in P8 animals.(**A**) Retino-collicular maps generated by the Leave-One-Out method at P8 in WT (n = 38 animals), Efna3KI/+ (n = 15 animals) and Efna3KI/KI (n = 43 animals) mutants. Grey lines represent each map for each leave-one-out run. Each dot represents an individual mouse. (**B--G**) P8 DiI retrograde labelling (red) coupled to immuno-staining (green) of EFNA3 (**B--D**) and ISL2 (**E--G**) in Efna3KI/KI (n = 4 animals) mutant retinas. Arrowheads indicate ISL2(+) / high EFNA3 DiI labelled RGCs. Scale bars represent 10 µm. (**H--K**) Anterograde labelling after focal DiI injections in the retina showing retino-geniculate projections from the temporal-ventral (**T--V**) (**H, I**) and nasal-ventral (**N--V**) (**J, K**) retinal quadrants between Efna3KI/KI (**H, J**), (n = 4 animals) and WT (**I**), (**K**), (n = 4 animals) P8 littermates. Scale bars represent 400 µm. (**L--Q**) Anterograde labelling after full-eye injections showing eye-segregation in P8 WT (n = 3 animals) SCs (whole-mount top view: **L**); coronal sections: M, (**M'**) and dLGN (**N**) and in Efna3KI/KI (n = 4 animals) SCs (whole-mount top view: **O**); coronal sections: P, (**P'**) and dLGN (**Q**). Scale bars represent 250 µm (**L--P'**), 100 μm (**N, Q**). WT, wild-type; GCL, ganglion cell layer; T, temporal; N, nasal; R, rostral; C, caudal; dLGN, dorsal lateral geniculate nuclei; SC, superior colliculus.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.005](10.7554/eLife.20470.005)10.7554/eLife.20470.006Figure 3---figure supplement 1.Anterograde DiI labelling showing the focal injection in the retina (white star in **A**) and the corresponding termination zones in the SC (**B**).Scale bars represent 400 µm. D, dorsal; N, nasal; T, temporal, V, ventral; R, rostral; C, caudal; SC, superior colliculus.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.006](10.7554/eLife.20470.006)10.7554/eLife.20470.007Figure 3---figure supplement 2.Representative examples of collicular parasagittal sections showing labelled anterograde retinal termination zones in P8 Efna3KI/KI (**A**) and WT (**B**) littermates.Insets show the corresponding retinal DiI injection indicated by a white arrow. Scales bars represent 400 µm. N, nasal; T, temporal; R, rostral, C, caudal; SC, superior colliculus; WT, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.007](10.7554/eLife.20470.007)

Cortico-collicular maps are duplicated in Isl2-Efna3KI mutants {#s2-2}
--------------------------------------------------------------

To test whether retinal EFNA guidance cues influence the formation of the V1 cortico-collicular map, we traced cortico-collicular projections from V1 cortex by focal DiI injection in P14 mice and analyzed the location of the TZs in the SC at P15. Quantitative analyses using ImageJ revealed a remarkable duplication of the cortico-collicular map for single injections along the lateral-medial axis of the V1 in 47% of Efna3KI/KI (n = 9/19, [Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}) and 43% of Efna3KI/+ (n = 7/16, [Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}) animals when compared to WT littermates (n = 9, [Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}) demonstrating heterogeneity of the phenotype in Efna3 KI mutants. If this heterogeneity is caused by genetic variations between animals, the same type of projections (either single or duplicated) should be observed in both colliculi of a given animal. This was not observed in 60% of Efna3KI/KI (n = 3/5) and 57% of Efna3KI/+ (n = 4/7) animals when we traced the cortico-collicular projections in both left and right colliculi ([Figure 4D,D'](#fig4){ref-type="fig"}). Therefore, genetic variation is unlikely to contribute to the map heterogeneity between animals of the same genotype. This heterogeneity is most likely the consequence of a stochastic process of map formation, as suggested previously ([@bib29]). In Efna3KI/KI animals showing the same type of projections between colliculi, (40% of the mice) all of these projections were duplicated whereas in the Efna3KI/+ animals, the remaining 43% presented only single projections in both left and right colliculi, suggesting an effect of the level of *Efna3* ectopic expression onto cortico-collicular map duplication. As expected, all WT animals tested (n = 4) showed single projections in both colliculi ([Figure 4D](#fig4){ref-type="fig"}).10.7554/eLife.20470.008Figure 4.Anterograde cortico-collicular mapping in P14 animals.(**A--C**) Cortico-collicular maps generated by the Leave-One-Out method at P15 in Efna3KI/KI (n = 19 animals) (**A**), Efna3KI/+ (n = 16 animals) (**B**) and WT (n = 9 animals) (**C**) mutant littermates. Grey lines represent each map for each leave-one-out run for duplicated and single maps. Each dot represent an individual mouse. (**A'--C'**) show examples of single (**A', B', C'**) and duplicated (**A'', B''**) cortical TZs in collicular sagittal sections from different genotype together with the corresponding injections in V1 (lower panels in **A'--C'**). The corresponding coordinates are labelled by red arrows (duplicated) or a black arrow (single). Scale bars represent 400 µm (**A'--C'**), 1 mm (insets in **A'--C'**). (**D--D'**) Percentage of heterogeneous duplicated/single (D/S) or homogeneous single/single (S/S) or duplicated/duplicated (D/D) projections in both colliculi of the same animal (**D**) (Efna3KI/KI, n = 5 animals; Efna3KI/+, n = 7 animals; WT, n = 4 animals). (**D'**) shows an example of cortico-collicular TZs from left and right colliculi and corresponding V1 injections in a P15 Efna3KI/+ animal. Scale bars represent 400 µm (for colliculi), 1 mm (for V1). (**E**) Mean separation between duplicated maps measured experimentally (ΔS~exp~) in Efna3KI/KI (median = 13%, 1^st^quartile = 10%, third quartile = 13%, n = 9 animals) and Efna3KI/+ (median = 7%, 1^st^quartile = 6%, third quartile = 9.5 % n = 7 animals) (non-parametric Mann and Whitney test, \*\*p=0.020). (**F**) Sagittal section of P15 Efna3KI/KI (n = 4 animals) DiI labelled cortical projection (left) and merged image of CTB-488 full-eye fill and cortical DiI projection (right). Scale bars represent 200 µm. L, lateral; M, medial; R, rostral; C, caudal; S, single; D, duplicated; TZ, termination zone; WT, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.008](10.7554/eLife.20470.008)10.7554/eLife.20470.009Figure 4---figure supplement 1.Representative examples of collicular parasagittal sections showing cortical terminations zones and the corresponding injections in V1 in Efna3KI/KI (**A**), Efna3KI/+ (**B**) and WT (**C**) P15 littermates.White panels show the termination zones analyses using ImageJ. Scale bars represent 1 mm (V1 whole-mount), 500 μm (SC), R: rostral, C: caudal, L: lateral, M: medial; WT, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.009](10.7554/eLife.20470.009)10.7554/eLife.20470.010Figure 4---figure supplement 2.Collicular termination zones on parasagittal sections revealed after double DiI -- DiD V1 anterograde injections in P15 Efna3KI/KI (**A**) and WT (**B**).White panels show the corresponding ImageJ termination zones analyses. Scale bars represent 1 mm (**V1**) SC, 500 µm (SC). R, rostral; C, caudal; L, lateral; M, medial; SC, superior colliculus; WT, wild-type.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.010](10.7554/eLife.20470.010)10.7554/eLife.20470.011Figure 4---figure supplement 3.Immunostaining revealing EFNA3 expression (green) in P3 (**A, D**) and P8 (**B--F**) Efna3KI/KI and WT SC parasagittal sections after retinal anterograde DiI injection (red fibers).Scale bars represent 30 µm (**A, D**), 10 μm (B - F).**DOI:** [http://dx.doi.org/10.7554/eLife.20470.011](10.7554/eLife.20470.011)10.7554/eLife.20470.012Figure 4---figure supplement 4.EFNA3 expression in Efna3 mutants and WT optic nerves.(**A--F**) Immunohistochemical staining revealing EFNA3 expression (green) in P3 and P8 Efna3KI/KI and WT SC parasagittal sections after retinal anterograde DiI injection (red fibers). Scale bars represent 30 μm (**A, D**), 10 μm (B - F). (**H**) Absence of EFNA3 in P8 Efna3-/- proximal optic nerve. Scale bar represents 20 µm. (**I--J'**) Co-immunostaining of EFNA3 (green) (**I--J'**) and NF200 (red) (**J, J'**) on P8 Efna3+/- proximal optic nerves validating the specificity of the antibody staining. Insets in (**I**) and (**J**) correspond to (**I'**) and (**J'**) respectively. Arrowhead in (**I'**) and (**J'**) show co-stained fibers. Scale bars represent 20 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.012](10.7554/eLife.20470.012)

Next, we calculated the average distance of separation (ΔS~exp~) between the duplicated maps in Efna3 KI mutants as a percentage of the rostral-caudal axis of the SC ([Figure 4A,B](#fig4){ref-type="fig"}). This revealed a significant two-fold difference in map separation between Efna3KI/KI (ΔS~exp~ median = 13%, n = 9) and Efna3KI/+ (ΔS~exp~ median = 7%, n = 7) animals, which correlates with the presence of one or two copies of the *Isl2-ires-Efna3* allele ([Figure 4E](#fig4){ref-type="fig"}). Since *Isl2* is not expressed in the cortex (see [Figure 5B](#fig5){ref-type="fig"}), these results suggest that *Efna3* ectopic expression in *Isl2*(+) RGC axons/TZs destabilizes the stochastic process of cortico-collicular mapping, leading to map duplication in Efna3 KI animals. This in turn implies that V1 EphA-positive cortical axons sense varying EFNA3 levels on RGCs terminals by direct contact with these terminals in the SC ([@bib5]) and anterograde labelling from retina and V1 cortex showed that both cortical and retinal axons terminals overlap in the superficial layers of the SC ([Figure 4F](#fig4){ref-type="fig"}) ([@bib31]; [@bib29]). To further analyze the presence of EFNA3 of retinal origin in the SC, we performed EFNA3 immunohistochemistry coupled to retinal DiI injections on collicular sections. DiI labelled RGC axons were observed in the SC, as well as a strong collicular EFNA3 staining ([Figure 4---figure supplement 3A--F](#fig4s3){ref-type="fig"}, [Figure 5---figure supplement 1A--D'](#fig5s1){ref-type="fig"}). However, no EFNA3 staining on single DiI-labelled RGC axons could be detected in neither Efna3KI/KI nor WT littermates ([Figure 4---figure supplement 3A--F](#fig4s3){ref-type="fig"}). EFNA3 immunohistochemistry on P3 Efna3KI/KI and WT optic nerve (ON) longitudinal sections (proximal, middle and distal to the optic cup) showed the presence of EFNA3 on fibers within the proximal part of the ON in Efna3KI/KI and WT littermates ([Figure 4---figure supplements 4A,A', D,D'](#fig4s4){ref-type="fig"}) but not on the proximal part of Efna3−/− ON ([Figure 4---figure supplement 4H](#fig4s4){ref-type="fig"}). EFNA3 signal was also detected in the middle part of the ON in Efna3KI/KI but not in WT ([Figure 4---figure supplements 4B,B', E,E'](#fig4s4){ref-type="fig"}) and was nearly impossible to discern in the distal part of Efna3KI/KI ON ([Figure 4---figure supplements 4C,C', F,F'](#fig4s4){ref-type="fig"}), indicating that EFNA3 is present on RGC axons. This was further confirmed by co-localization of EFNA3 with NF200 on fibers ([Figure 4---figure supplement 4I--J'](#fig4s4){ref-type="fig"} and [Figure 1B--F,O--Q'](#fig1){ref-type="fig"}). Retrograde labelling confirmed that the cortico-collicular projections originate from layer V neurons in V1 cortex in P14 Efna3KI/KI animals ([Figure 5A](#fig5){ref-type="fig"}). No bi-cistronic expression of *Isl2-ires-Efna3* in either SC or V1 cortex of WT and Efna3KI/KI animals could be detected ([Figure 5B](#fig5){ref-type="fig"}), ruling out any indirect effects of *Efna3* ectopic expression. Transcript analyses in colliculi and V1 cortices revealed similar levels of *Efna2/a3/a5* and *Epha4/a7* receptors in Efna3KI/KI compared to WT littermates at P7 ([Figure 5C](#fig5){ref-type="fig"}) excluding indirect effects due to local changes of *Ephas/Efnas* gene expression. Similar level of EFNA3 between Efna3KI/KI and WT littermates was further confirmed by immunostaining of EFNA3 ([Figure 5---figure supplement 1A--E](#fig5s1){ref-type="fig"}).10.7554/eLife.20470.013Figure 5.V1 retrograde labelling and *Ephas/Efnas* quantitative expression in V1 and SC.(**A**) Retrograde labelling by collicular DiI injection in P14 Efna3KI/KI (n = 4 animals) and WT (n = 3 animals) showing the localization of the projecting V1 cortical neurons in layer V (DiI, red; DAPI, bue). Scale bars represent 100 µm. (**B**) PCR amplification products from P7 RNA (35 cycles) in Efna3KI/KI (n = 3 animals per genotype). A single amplicon of 90 bp, corresponding to an amplified sequence located in the *ires* cassette of the targeted construct, is observed only in Efna3KI/KI retina. (**C**) Box-plot of *Efna2/a3/a5* and *Epha4/a7* mRNA fold-expression levels relative to wild-type (WT) at P7 in the superior colliculus and V1 cortex of Efna3KI/KI mutants (n = 4 animals for each genotype, two colliculi/V1 per animal, variables are normally distributed, one sample t-test: superior colliculus: *Efna2*, p = 0.17; *Efna3*, p = 0.48; *Efna5*, p = 0.50; *Epha4*, p = 0.09; *Epha7*, p = 0.26 -- V1 cortex: *Efna2*, p = 0.09; *Efna3*, p = 0.61; *Efna5*, p = 0.84; *Epha4*, p = 0.07; *Epha7*, p = 0.58).**DOI:** [http://dx.doi.org/10.7554/eLife.20470.013](10.7554/eLife.20470.013)10.7554/eLife.20470.014Figure 5---figure supplement 1.EFNA3/DAPI immunohistochemical staining in P3 (**A -- A'**, (**C, C'**) and P8 (**B -- B'**, (**D**), (**D' E**) Efna3KI/KI (**A -- B'**), WT (**C -- D'**) and Efna3-/- (**E**) SCs sagittal sections.R, rostral; C, caudal. Scale bars represent 200 µm (**A--D'**), 100 µm (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.20470.014](10.7554/eLife.20470.014)

Genetic cis-inactivation of ectopic EFNA3 expression in RGCs restores a wild-type cortico-collicular map {#s2-3}
--------------------------------------------------------------------------------------------------------

If the defective cortico-collicular maps in the Efna3 KI animals were solely due to *Efna3* ectopic expression in *Isl2*(+) RGCs, then inactivation of this ectopic expression should rescue the phenotype and restore a wild-type map. Previous work showed that co-expression of EFNA3 ligand and EPHA3 receptor in the same cell leads to their mutual inactivation through cis-masking ([@bib13]). To accomplish this in vivo, we generated double heterozygous mice carrying *Epha3* on one allele of the *Isl2* gene and *Efna3* on the second allele (Epha3KI/Efna3KI). Immunohistochemical staining confirmed co-expression of EFNA3 and EPHA3 in acutely isolated double heterozygous RGCs ([Figure 6A](#fig6){ref-type="fig"}). Importantly, previous studies demonstrated that ectopic expression of the EPHA3 receptor in *Isl2*(+) RGCs in heterozygous Epha3KI/+ animals results in a duplicated retino-collicular map ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [@bib3]). Remarkably, co-expression of *Epha3* and *Efna3* in Epha3KI/Efna3KI double-mutant mice reverted the duplications, leading to normal retino- and cortico-collicular maps ([Figure 6B,C](#fig6){ref-type="fig"}). This double rescue of both maps indicates that cortico-collicular defects in Efna3 KI animals were caused by ectopic expression of EFNA3 in *Isl2*(+) RGCs and were restored by concomitant expression of EPHA3. The cis-inactivation mechanism was cross-validated by the presence of a normal retino-collicular map in the Efna3KI/Epha3KI double mutant mice, indicating EPHA3 inactivation ([Figure 6C](#fig6){ref-type="fig"}). To further evaluate any residual EFNA3 or EPHA3 signaling activity, we generated *Epha3KI/Efna3KIxEpha4* knock-in/out compound mutants. In these mice, decreasing the overall level of retinal EPHA receptors by eliminating EPHA4 expression would reveal subtle changes in retinal EPHA signaling strength ([@bib33]; [@bib2]). According to the Relative Signaling model in the *Epha3KI/+::Epha4+/−* and *Epha3KI/+::Epha4−/−* compound mutant animals analyzed previously ([@bib33]) any residual EPHA3 signaling on map formation would generate duplicated retinal TZs, particularly in the caudal part of the SC where nasal RGCs axons, expressing low levels of EPHA receptors, project. Retinal DiI anterograde tracing revealed no retino-collicular duplications, even in the caudal-most pole of the SC, in *Epha3KI/Efna3KI::Epha4+/-* and *Epha3KI/Efna3KI::Epha4−/−* compound mutants, confirming inactivation of EPHA3 and EFNA3 in *Isl2*(+) RGCs ([Figure 6D,E](#fig6){ref-type="fig"}). Altogether, these results suggest that EPHA3 and EFNA3 ectopic expression in the same RGCs lead to their mutual inactivation and confirm that cortico-collicular mapping duplications observed in Efna3 KI animals are the consequence of retinal EFNA3 ectopic expression.10.7554/eLife.20470.015Figure 6.Retino- and cortico-collicular maps in *Epha3KI/Efna3KI* double heterozygous and compound *Epha3KI/Efna3KI::Epha4* knock-in/out mutants.(**A**) Co-immunostaining of EFNA3 (LS-C6547, LS-Bio; green) and EPHA3 (red) in P4 acutely isolated Epha3KI/Efna3KI (n = 8 animals/15 retinas) RGCs. Arrowheads indicate EPHA3/EFNA3 co-expression in the same RGCs. Scale bars represent 10 µm. (**B, C**) Cortico-collicular (n = 11 animals) (**B**) and retino-collicular (n = 18 animals) (**C**) maps generated by the Leave-One-Out method at P15 and P8 respectively in Epha3KI/Efna3KI double mutants. (**D, E**) Examples of retino-collicular projections for nasal and temporal retinal injections in P8 *Epha3KI/Efna3KI::Epha4+/-* (n = 6 animals) (**D**) and *Epha3KI/Efna3KI::Epha4-/-* (n = 6 animals) (**E**) mutants. Scale bars represent 200 µm. T, temporal; N, nasal; R, rostral; C, caudal; L, lateral; M, medial; RGCs, retinal ganglion cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.015](10.7554/eLife.20470.015)10.7554/eLife.20470.016Figure 6---figure supplement 1.Retino-collicular map in P7 Epha3KI/+ mutants (n = 11 animals).T, temporal; N, nasal; R, rostral; C, caudal.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.016](10.7554/eLife.20470.016)

In silico modelling and theoretical analysis of cortico-collicular map alignment {#s2-4}
--------------------------------------------------------------------------------

Our results indicate that the level of EFNA3 on RGC projections innervating the SC influences the mapping and alignment of cortico-collicular projections. To simulate and explore the mechanism of map alignment, we created a 3-step map alignment model based on an algorithm originally developed to model retino-collicular mapping ([@bib42]; [@bib41]; [@bib29]). Our version generates first the retino-collicular map based on retinal *Epha* receptors and collicular *Efna* ligands graded expression. The second step transposes the retinal *Efna* gradients onto the rostral-caudal axis of the SC according to the layout of the retino-collicular map generated in step one. In the third step, the cortico-collicular map is generated based on cortical *Epha* receptors expression and the transposed retinal *Efnas* in the SC. Each map is generated by a stochastic process based on balanced forces between repellent EPHA forward signaling and associating correlated neuronal activity ([@bib42]; [@bib41]; [@bib29]) (see Experimental Procedures). To improve the validity of our model, we replaced the theoretical values of the retinal EPHA and EFNA gradients previously used ([@bib42]; [@bib41]; [@bib30]; [@bib29]) by our experimental quantification of retinal *Epha* mRNAs ([@bib33]) (R~A~(x)^retina^) and *Efna* mRNAs (L~A~(x)^retina^) ([Figure 7A,B](#fig7){ref-type="fig"}) reasonably assuming, as made previously ([@bib33]), that the measurement of mRNA differences translates linearly into differences in protein expression. L~A~(x)^retina^ best fit equations are:$$L_{A5}(x)^{retina} = (1/0.56)^{\ast}exp( - 0.014x)\quad R^{2} = 0.97$$$$L_{A2}(x)^{retina} = (1/0.54)^{\ast}exp( - 0.008x)\quad R^{2} = 0.93$$$$L_{A3}(x)^{retina} = 0.44\qquad\qquad\qquad\quad\qquad R^{2} = 0.97$$10.7554/eLife.20470.017Figure 7.Retinal Efnas quantification.(**A**) Section of P2 mouse retina (n = 6 retinas from three animals from different litters) hybridized with *Efna5*, *Efna2* and *Efna3* probes. Quantification was performed for 10 segments of the RGC layer along the nasal-temporal axis. Scale bar represent 100 µm. (**B**) *Efna2/a3/a5* expression profiles (dots) fitted by the equations (lines) corresponding to [equations (1), (2) and (3)](#equ1 equ2 equ3){ref-type="disp-formula"} respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.017](10.7554/eLife.20470.017)

The total *Efna* gradients in the WT retina is:$$\begin{matrix}
{L_{A}(x)^{retina\ WT}} & {= L_{A5}(x)^{retina} + L_{A2}(x)^{retina} + L_{A3}(x)^{retina}} \\
{L_{A}(x)^{retina\ WT}} & {= (1/0.56)^{\ast}exp( - 0.014x) + (1/0.54)^{\ast}exp( - 0.008x) + 0.44} \\
\end{matrix}$$

The total *Efna* gradients in the mutant retinas are:$$\begin{matrix}
{L_{A}(x)^{retina\ KI} = L_{A}(x)^{retina\ WT} + \Delta L_{A3}\,} & {with\ \Delta L_{A3} = 0.22\ in\ Efna3KI/ +} \\
 & {and\ \Delta L_{A3} = 0.44\ in\ Efna3KI/KI} \\
{L_{A}(x)^{retinaKI/ +} = (1/0.56)^{\ast}exp( - 0.014x)} & {+ (1/0.54)^{\ast}exp( - 0.008x) + 0.44 + 0.22} \\
\end{matrix}$$$$L_{A}(x)^{retina\ KI/KI} = (1/0.56)^{\ast}exp( - 0.014x) + (1/0.54)^{\ast}exp( - 0.008x) + 0.44 + 0.44$$

Equations were derived from semi-quantitative in situ hybridization as performed previously ([@bib33]) ([Figure 7A,B](#fig7){ref-type="fig"}) and from our transcripts analyses measuring the relative expression levels of *Efnas* in acutely isolated RGCs ([Figure 2C](#fig2){ref-type="fig"}). We observed graded expression of *Efna2* and *Efna5* along the nasal-temporal axis of the retina, whereas *Efna3* is homogeneously expressed in WT animals ([Figure 7A,B](#fig7){ref-type="fig"}). Curve fitting analysis using MATLAB revealed the equation L~A~(x)^retina\ WT^ modelling WT retinal *Efna* ligands expression along the nasal-temporal axis ([Equations 1-4)](#equ1 equ2 equ3 equ4){ref-type="disp-formula"}. The two-fold increase of *Efna3* in Efna3KI/KI RGCs compared to WT ([Figure 2C](#fig2){ref-type="fig"}) was included into the model by adding a constant ΔL~A3~ to L~A~(x)^retina\ WT^ thus generating the L~A~(x)^retina\ KI^ alternating ectopic expression in the Efna3 KI retinas ([Equation 5, 6](#equ5 equ6){ref-type="disp-formula"}). The 3-step map alignment model simulates the sequential mapping of 100 RGCs onto a 1D array of 100 SC neurons along the rostral-caudal axis, followed by 100 V1 cortical neurons innervating the SC. We made two assumptions: (1) endogenous collicular EFNAs are no longer active for incoming V1 axons as they have been engaged previously in RGCs axon guidance by binding to retinal EPHAs (forward signaling) which leads to the cleavage of their extracellular domains ([@bib18]), (2) retinal EFNA3 alone cannot provide positional information in the SC as its expression is not graded in the RGCs. Consequently, a proportion of graded retinal EFNA2/A5 acts together with retinal EFNA3 to provide positional information in the SC. After 10^7^ iterations per run (n = 20 runs) for each genotype, stable and organized retino-collicular maps were formed ([Figure 8A,D,G](#fig8){ref-type="fig"}). Thereafter, a proportion of retinal *Efna* gradients were transposed in the SC ([Figure 8B,E,H](#fig8){ref-type="fig"}) following to the retinal projections layout and then the cortico-collicular maps are generated in a similar fashion ([Figure 8C,F,I](#fig8){ref-type="fig"}). To account for map heterogeneity observed experimentally, we further analyzed the maps generated using a linear regression ([Figure 8C,F,I](#fig8){ref-type="fig"}, red lines) and an exclusion parameter (EP) ([Figure 8F,I](#fig8){ref-type="fig"}, dashed grey lines), which corresponds to the variability of the WT single map ([Figure 8C](#fig8){ref-type="fig"}, dashed grey lines, σ~WT~= 2.18 %) added to the genotype-specific average map separation (ΔS~exp~) calculated in Efna3 KI animals ([Figure 4E](#fig4){ref-type="fig"}, EP~KI/KI~ = 15.18%; EP~KI/+~ = 9.18 %; [Figure 8F,I](#fig8){ref-type="fig"}). The points, simulating the position of the cortico-collicular TZs along the rostral-caudal axis of the SC, located outside EP correspond to duplicated projections whereas the points located within EP correspond to single projections ([Figure 8F,I](#fig8){ref-type="fig"}). The percentages of duplicated projections generated by the model were similar to the percentages of experimentally measured duplications ([Figure 4A,B](#fig4){ref-type="fig"}) for both Efna3KI/KI and Efna3KI/+ animals (one sample t-test, *Efna3KI/KI*, p = 0.17; *Efna3KI/+*, p = 0.22; [Figure 8J](#fig8){ref-type="fig"}).10.7554/eLife.20470.018Figure 8.Theoretical analysis and modelling.(**A--I**) Retino- (**A, D, G**) and cortico- (**C, F, I**) collicular maps generated by the 3-step Map alignment model in WT (**A, C**), Efna3KI/KI (**D, F**) and Efna3KI/+ (**G, I**) after n = 20 runs and 10^7^ iteration/run. The parameters used for the retino-collicular modelling in the three genotypes are identical. Translated retinal Efn-As gradients (% of retinal expression: *Efna2* = 100%, *Efna3* = 100% and *Efna5* = 80%) into the SC in WT (**B**), Efna3KI/KI (**E**) and Efna3KI/+ (**H**). Red lines in (**C, F, I**) represent the linear regression. Variability of the WT map in (**C**) is calculated by σ~WT~ = 2.18% (n = 20 runs). Grey lines in (**F, I**) represent the exclusion parameter (EP) corresponding to EP = σ~WT~ + ΔS~exp~: EP~KI/KI~ = 15.18%, EP~KI/+~ = 9.18%. (**J**) Dot plot representation of the percentage of duplicated cortico-collicular projections (observed versus theoretical) for n = 20 runs in Efna3KI/KI (experimental = 47%, n = 9 animals; theoretical mean = 46.1%, ±95 %CI = 1.2%, one sample t-test, t = 1.42, 19 d.f., p = 0.17) and Efna3KI/+ (experimental = 43%, n = 7 animals; theoretical mean = 41.4%, ±95 %CI = 2.4%, variables are normally distributed, one sample t-test, t = 1.28, 19 d.f., p = 0.22) (theoretical Efna3KI/+ vs Efna3KI/KI, two-sample t-test, t = 3.4, 38 d.f., \*\*\*p = 0.0016). N, nasal; T, temporal; L, lateral; M, medial; R, rostral; C, caudal.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.018](10.7554/eLife.20470.018)

These results indicated that the 3-step map alignment model simulates both the retino- and cortico-collicular mapping and accurately recapitulates the normal and defective visual maps. It predicts the stochastic nature of the mapping abnormalities in Efna3KI/+ and Efna3KI/KI animals due to the *Efna3* ectopic expression in a subset of RGCs. Hence the model provides further evidence that retinal EFNA3 contributes to the alignment of the cortico-collicular map by providing positional information in the SC for ingrowing V1 axons carrying EPHAs.

Discussion {#s3}
==========

EPHAs and EFNAs are present in opposed gradients within visual areas and in corresponding gradients between connected areas. These features preclude the identification of basic molecular mechanisms using full knock-out approaches. We therefore generated a unique and powerful mouse model in which gradients of EFNAs are *quantitatively* perturbed in the *RGCs only*. Together with theoretical modelling, we describe a molecular mechanism and associated principles governing the alignment of converging topographic neural maps in the brain.

Retinal EFNA3 in cortico-collicular mapping {#s3-1}
-------------------------------------------

We showed that modestly elevated expression of EFNA3 exclusively in a subset of RGCs disturbed cortico-collicular map alignment in the SC, pointing to a mechanism where retinal EFNA3 provides positional information to ingrowing V1 cortico-collicular axons. Further confirmation came from the genetic inactivation of ectopic EFNA3 using co-expressed EPHA3 receptor. EPHA3/EFNA3 coexpression in the same cell, including RGCs, abolishes their trans-binding to EFNAs and EPHAs ([@bib10]; [@bib17]; [@bib28]; [@bib7]; [@bib13]; [@bib20]). We therefore generated double heterozygous mutants, Efna3KI/Epha3KI. The power of this approach resides in the fact that each individual Efna3KI/+ and Epha3KI/+ mutant shows robust visuotopic map abnormalities ([@bib3]; [@bib39]). The presence of WT retino- and cortico-collicular maps in the Efna3KI/Epha3KI double heterozygous mutants provides compelling evidence that both EFNA3 and EPHA3 were inactivated in *Isl2*(+) RGCs. Further evidence of EFNA3/EPHA3 inactivation came from the presence of normal retino-collicular maps in compound mutants *Efna3KI/Epha3KI::Epha4* knock-in/out mutants. Although we cannot rule out the occurrence of an altered expression/function of other yet unidentified molecules involved in mapping (e.g., semaphorins, L1) by ectopic EFNA3 expression, our results confirm the causal role of retinal EFNA3 ectopic expression on cortico-collicular alignment defects. They suggest that retinal projections play an instructive role in cortico-collicular map formation.

The heterogeneity of the cortico-collicular phenotype in the Efna3 KI mutants, revealed by a mix of single and duplicated projections, is in accordance with previous data showing a variable penetrance of the retinotopic mapping abnormalities in constitutive or conditional *Efnas* knock-outs ([@bib14]; [@bib6]; [@bib36]; [@bib29]). Such variable penetrance of the mutant phenotype can be explained by the stochastic nature of map formation driven by opposing forces resulting from EPHA signaling, which tends to separate neighboring RGCs through repulsion, and correlated neuronal activity, which tends to reinforce neighboring RGCs projections on adjacent target cells ([@bib6]; [@bib39]; [@bib29]). The general pattern of V1 collicular projections is consistent with the involvement of cortical EPHA receptor gradients (high-lateral to low-medial) ([@bib5]) repelled by low-rostral to high-caudal EFNA gradients of retinal origin in the SC (forward signaling). In the Efna3 KI animals, retinal EFNA3 oscillation in the SC organizes neighbor-neighbor relationships of V1 and RGC TZs locally through repulsion inducing a small distance of map duplication. Our model is consistent with a retinal-matching model, suggesting that retinal inputs are required for proper cortico-collicular mapping ([@bib19]; [@bib39]; [@bib4]).

In our model, retinal inputs carry molecular cues, EFNA3 and likely other retinal EFNAs present at the level of the TZs to provide positional information for ingrowing V1 axons ([Figure 9](#fig9){ref-type="fig"}). EFNA3 could be detected on RGC axons by immunohistochemical staining on proximal and middle parts of the optic nerve but fell below detection limit in the distal part and in the SC. We cannot exclude that a proportion of collicular EFNAs also contributes to the cortico-collicular mapping process. Altogether, our data suggest that transposed retinal EFNAs in the SC instruct cortico-collicular map alignment and act together with correlated neuronal activity pattern shared between RGCs and V1 axons ([@bib39]; [@bib4]). Triplett and collaborators ([@bib40]) suggested a gradient-matching model which posits that collicular EFNAs are required for the mapping of somatosensory inputs to the SC. These inputs behave similarly to the retino-collicular projections as they also require collicular EFNAs, although in different layers. In contrast, the requirement of SC-produced EFNAs for cortico-collicular mapping is unlikely. As mentioned by Triplett and colleagues, in this particular scenario, cortico-collicular projections in previously characterized Epha3KI/KI mutants would have led to a single TZ in the SC, leading to a mismatch between cortico- and retino-collicular maps. However, this was not observed ([@bib39]).10.7554/eLife.20470.019Figure 9.Schematic representation of the map alignment mechanism.RGCs axons in WT and Efna3 KI animals project to the SC during the first postnatal week and form the retino-collicular map through forward signaling activated by collicular EFNAs and fiber-fiber interactions (left side). In both WT and Efna3 KI animals, the retino-collicular map is single and coherent. In WT and Efna3 KI, each RGCs axon is loaded with a different concentration of retinal EFNAs (high-nasal, low-temporal) carried to the SC. Due to the coherence of the retino-collicular map, a smooth retinal EFNAs gradient is formed in the SC in WT, whereas in Efna3 KI animals, *Isl2*(+) RGC axons carry extra EFNA3 (in red) which creates an oscillatory retinal EFNAs gradient once transposed in the SC (right side). During cortico-collicular mapping, V1 axons carrying EPHA receptors are facing a smooth gradient of retinal EFNAs in the SC, leading to a single coherent map in WT. In Efna3 KI animals, V1 axons carrying EPHA receptors are facing an oscillatory gradient of retinal EFNAs (due to ectopic expression of EFNA3 in *Isl2*(+) RGCs) which leads to the duplication of the cortico-collicular map (43% in Efna3KI/+ and 47% in Efna3KI/KI) through local neighbor--neighbor relationships of V1/RGCs TZs via repulsion. C, caudal; R, rostral; WT, wild-type; TZ, termination zone; RGCs, retinal ganglion cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.019](10.7554/eLife.20470.019)

Retinal EFNA3 in retino-collicular mapping {#s3-2}
------------------------------------------

The presence of non-duplicated retino-collicular maps in both Efna3KI/+ and Efna3KI/KI mutants, as revealed by DiI tracing, suggests that retinal EFNA3 does not play a significant role in the formation of this map, consistent with previous work on Efna3-null mutants ([@bib30]). Several hypotheses have been raised as to how retinal EFNAs may participate in retino-collicular map formation using in vitro, ex vivo and in vivo approaches in mouse and chick. For example, EFNAs on RGC axons are activated by collicular EPHAs (reverse signaling), leading to axon repulsion ([@bib32]; [@bib24]; [@bib47]) or branch inhibition in the SC ([@bib45]). In our mouse model, this mechanism would generate a segregation between *Isl2*(−) and *Isl2*(+) RGC axons in the SC, the latter being more repelled by collicular EPHAs. However, such a segregation did not occur, suggesting that retinal EFNA3 is not involved in such a repulsive mechanism by collicular EPHAs. In vitro and in vivo transfection in chick neurons suggested that retinal EFNAs bind to co-expressed retinal EPHAs in the same RGCs leading to inactivation/masking of the EPHA receptors rendering those axons less sensitive to EFNAs binding in the target tissue ([@bib10]; [@bib17]; [@bib27]; [@bib28]; [@bib46]; [@bib7]). In our model, this mechanism would lead to a stronger inactivation of the EPHA4/A5/A6 receptors in the *Isl2*(+) RGCs expressing high levels of EFNA3, compared to RGCs with normal EFNA3 expression level. This would create two population of RGCs with different EPHA signaling strength, similarly to the EphA3KI mutants ([@bib3]; [@bib33]; [@bib39]; [@bib2]). In this context, according to the Relative Signaling model ([@bib3]; [@bib33]; [@bib2]), duplicated retino-collicular maps (partial or full) should be observed. Our results rather indicate that EFNA3 ectopic expression does not inactivate endogenous co-expressed EPHA4/A5/A6 receptors in RGCs. Nevertheless, we showed specific inactivation of EPHA3 by ectopic EFNA3, suggesting distinctive interactions in cis between EFNA/EPHA pairs as previously observed ([@bib46]; [@bib13]; [@bib20]). Conditional ablation revealed that high retinal EFNA5 on nasal RGCs axons prevents temporal RGC axons from targeting the caudal SC through fiber-fiber interaction ([@bib36]). In our mice, such a mechanism would have generated a local duplication between *Isl2*(+) and *Isl2*(-) RGCs or an extension of the TZs in the SC which was not observed, suggesting that retinal EFNA3 is not involved in fiber-fiber interaction. However, our results do not exclude the contribution of the fiber-fiber interaction mechanism to retino-collicular map development. Together with recent results ([@bib36]), our data further suggest that retinal EFNA3 and EFNA5 present distinct effects on visuotopic mapping and imply a member-specific role of retinal EFNAs in map formation. This is in contrast with retinal EPHA receptors which are considered to be functionally interchangeable ([@bib33]; [@bib2]).

Theoretical modelling further confirms mapping mechanism {#s3-3}
--------------------------------------------------------

Previous work modelled the stochastic nature of retino-collicular map formation based on the Koulakov model ([@bib42]; [@bib41]; [@bib29]). Here, we have substantially modified and expanded this algorithm using our measured *Efna* expression data instead of theoretical values and simulated the retino- and cortico-collicular mapping process sequentially. We assumed that retinal *Efna3* expression alone cannot provide positional information, due to its homogeneous expression profile in WT RGCs. Therefore other EFNAs or other guidance molecules, either retinal or collicular, must participate in the regulation of map alignment. Retinal EFNA5 has been recently shown to participate in RGCs fiber-fiber interactions ([@bib36]) but a given proportion may contribute to map alignment. We chose to retain 80% of the retinal EFNA5 level and 100% of retinal EFNA2/A3 levels in the algorithm. Moreover, contribution of endogenous collicular EFNAs to cortico-collicular map alignment seems unlikely as these mediated previous RGCs axons guidance ([@bib18]), therefore collicular EFNA levels were not included in the V1 projection step of the model. The 3-step map alignment model replicates experimental features of both retino- and cortico-collicular maps observed in WT and Efna3 KI animals. It validates a stochastic mechanism of retinal-dependent molecular cues, involving EFNA3, providing positional information in the SC for V1 axons which then coordinate with correlated neuronal activity ([@bib39]) to align visuotopic maps.

These data raise important new questions as to the function of the different endogenous EFNAs in the formation of topographic maps, requiring additional development of cell-specific gene targeting approaches. From a functional standpoint, this new principle may serve as a general framework for sensory map alignment, where positional information, carried by a leading map, acts together with correlated activity, enabling precise adjustments of subsequent projection alignment.

Materials and methods {#s4}
=====================

Generation of the Isl2-Efna3KI mice, animals and housing {#s4-1}
--------------------------------------------------------

The targeting construct containing a ribosomal entry site (IRES) followed by the mouse *Efna3* ORF-*SV40*polyA and the selection cassette PGK-*Neo* was inserted by homologous recombination into the 3\' untranslated region of the *Islet-2* gene locus as previously performed ([@bib3]). The mouse line was generated by the Mouse Clinic Institute, project IR3483 (Illkirch-France) in a C57/Bl6J background. Mice were hosted in a 12 hr/12 hr light-dark condition, fed ad lib. at the CNRS UMS3415 Chronobiotron (Strasbourg -- France). All procedures were in accordance with national (council directive 87/848, October 1987) and European community (2010/63/EU) guidelines. Official agreement number for animal experimentation is A67-395, protocol number 01831.01 (M.R). Male and female C57/Bl6J *Efna3KI*, *Epha3KI* and *Epha4KO* mice and pups were genotyped by PCR from genomic DNA from tail biopsies as described previously ([@bib11]; [@bib33]). Primers are available in Supplementary Files. Immunohistochemistry and mapping analyses were made blind to genotype.

Projections analysis/mapping {#s4-2}
----------------------------

Anterograde and retrograde DiI (1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate), DiD (1,1\'\--dioctadecyl-3,3,3\',3\'- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate) and/or retrograde CTB-488 (Cholera Toxin B subunit-Alexa 488) labelling were performed as described ([@bib33]; [@bib39]). Whole-mount SC were processed as described and TZs were plotted along the rostral-caudal axis on Cartesian coordinates (y axis) ([@bib33]). For cortico-collicular map analyses, sagittal vibratome sections were performed on P14 SC and TZs were plotted along the rostral-caudal axis on Cartesian coordinates (y axis). Retinas were dissected and imaged using Zeiss Axioscope two and Axiovision software. Retinal coordinates of the DiI injections were calculated using IntactEye algorithm ([@bib16]), confirmed using the projection method ([@bib33]) and plotted on Cartesian coordinates (x axis). V1 cortices were photographed as whole-mount and focal injections plotted along the V1 lateral-medial axis (x axis) ([@bib39]). Retino-collicular and cortico-collicular maps were generated using non-parametric smoothing technique, termed LOESS smoothing ([@bib12]), to estimate the profile of the one-dimensional mapping either from retina to SC, or from V1 to SC. To estimate the variability in a mapping containing N data points, we repeated the procedure N times with N-1 datapoints, each time dropping a different datapoint. This is termed a 'leave-one-out' method and was used in the R Project for Statistical Computing (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)). The script is available in [Source code 1](#SD1-data){ref-type="supplementary-material"} file. Retino-geniculate and binocular tracings were performed as described ([@bib30]) on Efna3KI/KI (n = 4) and WT (n = 3) P7 animals. Analyses of the cortico-collicular projections were performed using the thresholding function in ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)).

Immunohistochemistry {#s4-3}
--------------------

Retinas, ONs, SCs and V1 cortices were dissected after animal perfusion with PFA4% in PBS1X, post-fixed O/N in PFA4%/PBS1X, cryoprotected in PFA4%/sucrose 30%/PBS1X for several hours at 4°C. Retinas and ONs were cryostat-sectioned (14--18 μm), SCs and V1 cortices were vibratome-sectioned (40 μm) and processed for immunohistochemistry. Experiments were performed at least three times. Briefly, sections were incubated in blocking solution (PBS 1X/BSA 1%/normal goat serum 10%) for 1 hr at RT then incubated with primary antibody O/N at 4°C in PBS 1X/BSA 1%/normal goat serum 1%. The following day, sections were washed (3 × 5\' in PBS 1X at RT) and incubated for 1 hr at RT with secondary Alexa-labelled antibodies in PBS1X/BSA 1%/normal goat serum 1%. After three washes at RT (3 × 5\' PBS 1X), slides were mounted in Aqua-Polymount (Polysciences Europe GmbH, Eppelheim, Germany) and visualized under a confocal microscope (Leica SP5 II, Leica Microsystems, Wetzlar, Germany). Sections were imaged using Leica LASAF software. Antibodies: anti-Isl2 (1/400, ref. LS-C165303, LifeSpan Biosciences Inc., RRID:[AB_2126601](https://scicrunch.org/resolver/AB_2126601)), anti-Efna3 (1/300, ref. LS-C6547, LifeSpan Biosciences Inc., RRID:[AB_797145](https://scicrunch.org/resolver/AB_797145)), anti-EphA3 (1/100, ref. LS-C150188, LifeSpan Biosciences Inc., RRID:[AB_11187174](https://scicrunch.org/resolver/AB_11187174)), anti-Efna3 (ref. 36--7500, 1/200, Invitrogen, Invitrogen Co. RRID:[AB_2533278](https://scicrunch.org/resolver/AB_2533278)), anti-synaptophysin (1/200, ref. S5768, Sigma-Aldrich), anti-Tau (1/200, MAB3420, Merck Millipore), anti-NF200 (1/200, ref. N5389, Sigma-Aldrich), anti-rabbit Alexa 488 (RRID:[AB_10373124](https://scicrunch.org/resolver/AB_10373124)), anti-goat Alexa 594 (RRID:[AB_10562717](https://scicrunch.org/resolver/AB_10562717)), anti-mouse Alexa 555 (RRID:[AB_10561552](https://scicrunch.org/resolver/AB_10561552)) (1/500, Invitrogen, Invitrogen Co.).

Quantitative RT-PCR {#s4-4}
-------------------

V1 cortices, superficial layers of the SC and retinas were freshly dissected. Retinas were cut in three equal pieces along the NT axis (Nasal, Central, Temporal RGCs) and RGCs acutely isolated ([@bib35]; [@bib9]). Total RNA was extracted and quantified as previously described ([@bib25]). Briefly, relative quantification was performed using the comparative Delta Ct method. Triplicates were run for each sample and concentration for the target gene and for two housekeeping genes (hypoxanthine-guanine phosphoribosyl transferase - *Hprt* and glyceraldehyde 3-phosphate dehydrogenase -- *Gapdh*) were computed. Primers are listed in Supplementary File.

Retinal ganglion cell isolation {#s4-5}
-------------------------------

P3/P4 retinas were freshly dissected and RGCs were isolated and purified (\>99%). For details see [@bib35]; [@bib9]). Briefly, cells were cultured in Neurobasal medium (Gibco/Invitrogen) supplemented with (all from Sigma, except where indicated) pyruvate (1 mM), glutamine (2 mM; Gibco/Invitrogen), *N*-acetyl-l-cysteine (60 μg ml^−1^), putrescine (16 μg ml^−1^), selenite (40 ng ml^−1^), bovine serum albumin (100 μg ml^−1^; fraction V, crystalline grade), streptomycin (100 μg ml^−1^), penicillin (100 U ml^−1^), triiodothyronine (40 ng ml^−1^), holotransferrin (100 μg ml^−1^), insulin (5 μg ml^−1^) and progesterone (62 ng ml^−1^), B27 (1:50, Gibco/Invitrogen), brain-derived neurotrophic factor (BDNF; 25 ng ml^−1^; PeproTech, London, UK), ciliary neurotrophic factor (CNTF; 10 ng ml^−1^; PeproTech) and forskolin (10 μm; Sigma). After isolation, RGCs were either treated for RNA extraction or fixed with PFA4% 15\' at RT and processed for immunohistochemistry. Stainings were performed and cells were visualized as described above.

Semi-quantitative in situ hybridization and gradient fitting of retinal Efnas expression {#s4-6}
----------------------------------------------------------------------------------------

Analysis of the expression of the *Efnas* was performed as previously described ([@bib33]) on nasal-temporal 20 μm thick sections of P1/P2 WT retinas. Probes used were: mouse *Efna2* (NM007909.3, 879 bp, pos. 387--1266), mouse *Efna3* (NM010108, 791 bp, pos. 208--999) and *Efna5* (NM207654, 696 bp, pos. 189--885). Experimental values (mean +SD, *Efna2/a3/a5*, for each *Efnas*, n = 18 sections total, 3 sections/retina, from 6 retinas −2 left, 2 right- from 3 animals) were plotted along the nasal-temporal axis and fitted using MATLAB (RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)).

In silico replication of the duplication of the cortico-collicular map {#s4-7}
----------------------------------------------------------------------

The Koulakov model in MATLAB (RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)) ([@bib42]; [@bib41]) was used to simulate the formation of both the retino- and cortico-collicular maps in the presence of an oscillatory *Efna* gradients in the target structure. Each brain structure (retina, SC, V1) is modelled as a 1-d array of 100 neurons (N) in each network. Two maps are generated: first, the map from retina to SC; second, the map from V1 to SC. Each map is modelled sequentially in the same way. This model consists in the minimization of affinity potential (E) which is computed as follows:$$E = E_{act} + E_{chem}$$

At each step, this potential is minimized by switching two randomly chosen axons probabilistically according to the degree such a switch reduces the energy in the system by Delta E (ΔE). The probability of switching, p, is given by: p=1/(1 + exp(4ΔE)).

E~chem~ is expressed as follows:$$E_{chem} = \sum_{i \in TZS}\alpha\lbrack R_{A}(i) - R_{A}(j)\rbrack\lbrack L_{A}(i^{\prime}) - L_{A}(j^{\prime})\rbrack$$

where α is the strength (α = 200), R~A~(i) and R~A~(j) the receptor concentration in the retina and V1 at location (i) and (j) and L~A~(i') and L~A~(j') the ligand concentration at the corresponding position (i') and (j') in the SC. The contribution of activity-dependent process is modelled as:$$E_{act} = - \gamma/2\sum_{ij \in synapses}C_{ij}U(r^{\prime})$$

where γ = 1 is the strength parameter, C~ij~ is the cross-correlation of neuronal activity between two RGCs (or V1) neurons during spontaneous activity located in (i) and (j), and U simulates the overlap between two SC cells. Here, we use Cij = exp(−r/R), where r is the retinal distance between RGC (i) and (j), R = 0.11 × N, and U(r') = exp(−r'^2^/2d^2^), where r' is the distance between two SC points (i', j'), d = 3 and N = 1 to 100 neurons.

Receptor and ligand gradients were modelled as follows:

Retinal *Epha* gradients ([@bib33]):$$R_{A}(x)^{retina} = 0.26^{\ast}exp(0.023x) + 1.05$$

Cortical V1 *EphA* gradients ([@bib42]; [@bib41]):$$R_{A}(x)^{V1} = exp( - x/N) - exp((x - 2N/(N)) + 1)$$

Collicular *Efna* gradients ([@bib42]; [@bib41]):$$L_{A}(x)^{SC} = exp((x - N)/N) - exp(( - x - N)/N)$$

L~A~(x)^retina^ is the *Efna* gradient which was modelled by an exponential fitting of the in situ hybridization data. These retinal *Efna* gradients (80% of *Efna5* expression and 100% of *Efna2* and *Efna3*) are transposed to the SC for the simulation of the cortico-collicular map.

Retinal *Efna* gradients equation along the nasal (0) -- temporal (100) axis (see Results):$$L_{A}(x)^{retina\ WT} = L_{A5}(x)^{retina} + L_{A2}(x)^{retina} + {L_{A3}}^{retina}$$$$L_{A}(x)^{retina\ WT} = (1/0.56) \ast exp( - 0.014x) + (1/0.54) \ast exp( - 0.008x) + 0.44$$

([Figure 7](#fig7){ref-type="fig"}) where x = 1 to N and N = 100 representing the neurons along each axes (L-M in V1, N-T in retina). When transposed along the rostral-caudal axis in the SC (retina → SC), retinal *Efna* gradients are flipped along the x axis and become:$$\begin{matrix}
{L_{A}(x)^{retina\rightarrow SC}} & {= (1/0.56)^{\ast}exp( - 0.014(100 - x)) + (1/0.54)^{\ast}exp( - 0.008(100 - x)) + 0.44} \\
 & \\
 & {= 0.56^{\ast}exp(0.014x) + 0.54^{\ast}exp(0.008x) + 0.44} \\
\end{matrix}$$

The oscillatory gradient was generated by randomly attributing to 50% of collicular TZs an overexpression of *Efna3* (ΔL~A3~) with ΔL~A3~ = 0.44 for homozygotes and ΔL~A3~ = 0.22 for heterozygotes. Iterations were ran for 10^7^ epochs. 3-step map alignment model scripts can be found in Source Code two file.

Quantitative analysis of theoretical maps {#s4-8}
-----------------------------------------

To determine the amount of duplication that could be found in heterozygotes and homozygotes mutants a linear regression was calculated using implemented functions in Matlab. The residuals were then used to calculate the percentage of duplication. Duplications were considered when values were outside EP = 9.18% for Efna3KI/+ and EP = 15.18% for Efna3KI/KI, which corresponds to the averaged experimental distances measured between duplicated termination zones (ΔS~exp~) to which was added the wild-type map variability (average of residuals, σ~WT~ = 2.18 %, n = 20 runs). Twenty runs were performed and averaged to find the proportion of duplicated termination zones for Efna3 KI.

Data/codes availability {#s4-9}
-----------------------

Software package IntactEye can be found at: <http://github.com/hjorthmedh/IntactEye>. 'Leave-one-out' script in R and 3-step Map Alignment Model provided as a source code files ([Source code 1](#SD1-data){ref-type="supplementary-material"} and [2](#SD2-data){ref-type="supplementary-material"}). Model also available at [@bib34] (with a copy archived at <https://github.com/elifesciences-publications/3-step-Map-Aligment-Model>).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"A Molecular Mechanism for the Topographic Alignment of Convergent Neural Maps\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and by Andrew King as Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation with the reviewers. Based on these discussions among the reviewers and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife* at this time.

All three reviewers considered your study important and felt it would be a valuable addition to the field. They described your finding that expression of ectopic ephrin-A3 in *Isl2(+)* RGCs creates a discontinuous gradient of ephrin-A3 on RGC axons, and that this provides repellent cues to guide V1 axons to topographically correct locations in the SC, as novel and potentially exciting.

The reviewers nonetheless had several suggestions for improvements that would strengthen the study, some of which will likely involve additional and somewhat lengthy experiments:

1\) Demonstration of the discontinuous gradient of ephrin-A3 protein in the SC. This may be understandably difficult to do if the antibodies are not good.

2\) In line with the discontinuity demonstration: a two-color V1 injection that would enable visualization of interdigitated red and green termination zones (TZs) in the SC. This would fortify your conclusions.

3\) The figure/micrograph quality is sub-par. One suggestion for getting a better read on duplication of the cortical maps would be to section the SC and to show the results at higher magnification than used in the current version, rather than showing surface images.

4\) in vitro assays as an alternative for demonstrating ki-ephrin-A3 on axons by checking for altered sensitivity of ephrin-A3 KI/KI axons to EphA3-Fc, using a collapse or similar assay.

5\) Revision of the assumptions and other aspects of the modeling, as indicated in reviewer 3\'s comments.

*Reviewer \#1:*

Savier et al. describe the changes in retinocollicular and V1-collicular maps when ectopic ephrin-A3 is expressed in *Isl2(+)* RGCs, creating a discontinuous gradient of ephrin-A3 on RGC axons. This is a similar approach to that used by Brown et al. 2000 and Triplett et al. 2009 that showed that to ectopically expressed EphA3 in *Isl2(+)* RGCs leads to map duplications in the retinocollicular and V1-SC projections. Unlike when EphA3 is ectopically expressed in the retina, the authors find that ectopic expression of ephrin-A3 does not affect the topography of the retinocollicular projection. Interestingly, retinal expressed ephrin-A3 leads to changes in the V1-SC topographic map. These results lead the authors to a computational model whereby RGC axons in the SC provide repellent cues to guide V1-SC axons to topographically correct locations.

This work is very interesting and timely and the authors propose a compelling model to explain the data in the context of topographic map alignment.

1\) I am confused why ectopic expression of ephrin-A3 in *Isl2(+)* RGCs does not lower the effective concentration of EphAs in these cells. The experiments in [Figure 6](#fig6){ref-type="fig"} show that extra EphA3 can mask the ectopic ephrin-A3. So why doesn\'t the ectopic ephrin-A3 mask the available EphA, especially in the nasal half of the retina where EphA levels are graded and low?

The authors address this in the Discussion \"However, we did not observe any retino collicular mapping defects regardless of the mutant genotypes, suggesting that ephrin-A3 ectopic expression does not inactivate endogenous co-expressed EphA4/A5/A6 receptors in RGCs, although we showed specific inactivation of EphA3, suggesting distinctive interactions in cis between ephrin-A/EphA pairs as previously observed (Yin et al., 2004; Falivelli et al., 2013; Klein and Kania, 2014).\" But this explanation is somewhat unsatisfying based on the current knowledge of ephrin-A binding affinities for EphA receptors.

It would be nice if the authors can address the specificity of masking more directly, perhaps by showing ectopic ephrin-A3 does not change the sensitivity of RGC axons to ephrin-A5 in trans, although I understand that this may be beyond the scope of the paper.

2\) It would be nice to directly visualize the discontinuity of ephrin-A3 expression on RGC axons in the SC using immunocytochemistry.

3\) The duplication of the V1-SC projection is not very pronounced. It seems possible that the termination zones are just a bit blurry. Two color DiI, DiO injections in V1 would unambiguously demonstrate that the TZs are duplicated (see Triplett et al. 2009 [Figure 6](#fig6){ref-type="fig"}).

4\) The SC s of the anterograde DiI retinal injections should be sectioned as done for the V1-SC projection. It is possible that ectopic termination zones in deeper SC lamina may not be revealed in a whole mount view.

*Reviewer \#2:*

The manuscript by Savier et al. describes a novel ephrinA3-based mechanism that guides the alignment of convergent topographic maps in the mouse superior colliculus. These findings add to a rich literature of how gradients of Eph Receptors and their ligands in the retina and brain lead to topographic maps. An interesting twist on the studies presented here is that retinal ganglion cells generate ephrin A3, and its presence on retinal terminals (or arbors) in the SC contribute to the mapping of cortical projections from V1 that converge on target cells in the SC. Several other sets of studies have now shown how one class of axons in a given visual target, dictate how other classes or types of axons innervate that same target (Triplett et al. 2009; Seabrook et al. 2013; Brooks et al. 2013; Grant et al. 2016; Shanks et al. 2016). That being said, little is known about what molecular cues on an axon may dictate this and for this reason this paper will be of interest to the field.

There are several strengths to this manuscript, including the generation of a novel mouse mutant in which ephrinA3 is over expressed in a subset of RGCs. This approach was previously used to misexpress EphA3, which led to the discovery that EphA3 overexpression leads to a duplication of retinocollicular maps. Interestingly, perturbing ephrinA3 expression in RGCs had little affect on retinocollicular or retinogeniculate circuits. Another strength of the manuscript is that the authors use a clever trick to inactivate ephrins and EphA3 by co-expressing a single allele each under the Islet2 promoter and they develop a novel computation model to support their experimental data.

There are, however, some weaknesses in the manuscript that require additional data and analyses. Without these changes this reviewer does not think this work is suitable for publication in *eLife*.

These major concerns include:

Is there an alteration of ephrinA3 distribution in the SC of the *Isl2(-)* ephrin-A3KI mice? EphrinA3 IHC was performed in this manuscript, but only in retina. For the model proposed to be valid (really the crux of the manuscript) one would expect to see fluctuations in ephrin A3 distribution in SC in mutants (associated with retinal arbors). This is an essential piece of data that is missing. And it should be done on WT, single copy mutants, and double copy mutants.

The duplications of cortical maps are quite subtle in these mutants, compared to those of previous studies. In fact, they are so subtle they are difficult to discern in some cases in the manuscript -- the images in [Figure 4B](#fig4){ref-type="fig"} both look like double maps compared to WT controls. How were double maps quantified and identified? It seems critical to show the injection sites in V1 for each case (like is done for retinocollicular maps) to ensure that double maps are not the result of wider injection sites. Likewise, an important part of the manuscript was that retinal maps are unaffected. But the analysis of those maps seems less detailed than the cortical maps. Perhaps subtle changes in retinal maps would be observed if sections of SC were analyzed at high magnification, rather than surface images. Again, consistency in analysis methods for both sets of maps and data is important for the conclusions of the manuscript.

While the inactivation of ephrinA3 overexpression by co-expression of EphA3 was viewed as a strength of the manuscript, some of the data demonstrating the validity of this approach was dumped into the supplemental material. It seems too important to be \"supplemental\" as it is a critical component of this manuscript. Likewise more data needs to be presented to convince this reviewer that this result is not the result of the lack of penetrance in single copy of EphA3 mutant, since it has been previously reported that duplicated maps are observed in only some single copy mutants.

In addition to major concerns described above, there are also concerns in the presentation of the manuscript:

1\) In some cases, images appear to be poorly selected to make the authors point. For example see [Figure 2A, B](#fig2){ref-type="fig"} which are described as being similar but are not of equal quality. Other examples include 3H-K, [Figure 4](#fig4){ref-type="fig"}, and [Figure 6D, E](#fig6){ref-type="fig"}.

2\) In several cases proper labeling is missing or inappropriate on the figures. In [Figure 1G, H](#fig1){ref-type="fig"} labels are missing. In [Figure 3N-O](#fig3){ref-type="fig"} what are the arrows? (And the figures in [Figure 3L-O](#fig3){ref-type="fig"} are insufficient to claim normal eye-specific segregation in this mutant). It's unclear what [Figure 5B](#fig5){ref-type="fig"} is amplifying? (And if its ephrinA3 why isn\'t it in WT retina?). More care should be paid to all figures and legends.

*Reviewer \#3:*

The formation of topographic axonal maps is a key element of brain wiring. Visuotopic mapping is mainly instructed by the ephrin/Eph system, enabling forward, reverse, axon/target, axon/axon and cis signals. The actual contribution of each of these signals and their integration, has remained highly controversial. The authors specifically address the role of axonally located ephrin-As by a knock-in (KI) of ephrin-A3 into a random half-population of retinal ganglion cells (RGCs). Therefore, their paper is of major importance to the field. Their approach is valid, the experiments are thoroughly performed, carefully evaluated and lucidly presented in the paper. I have, however, two (somewhat) major issues that should be clarified before publication.

Based on our current understanding, a duplicated retinocollicular map in the KI/KI animals would be expected. Ki axons should grow to the posterior superior colliculus (SC) due to axon/target reverse signaling (Rashid T., et al. 2005). Wildtype axons should be anteriorly displaced due to axon/axon forward signaling (Suetterin P., et al., 2015). Intriguingly, the retinocollicular map is unaffected by the ki. In contrast, however, the V1-corticocollicular map is split up, notably indicating a role of ephrin-A3 on retinal axons in the chemotopic guidance of V1 cortical axons. The same projection has previously been claimed to be aligned by activity-dependent mechanisms (Triplett J., et al., 2009). Although very exciting, the new results are to some degree in conflict with previous observations, necessitating thorough control. Thus, I\'m still not fully convinced, that an amount of KI ephrin-A3 arrives in the SC that could be functionally relevant to retinocollicular mapping. Maybe the pioneering retinocollicular mapping is more robust to changes than the following corticocollicular map. Immunostainings of isolated kiRGCs display labeling on the neurites ([Figure 1O, O](#fig1){ref-type="fig"}\'), but this is after 6 DIV and it remains unclear whether the shown neurites are axons or dendrites. The authors show that concomitant KI of EphA3 rescues the mapping effects of both knock-ins, but the mutual neutralization of ephrin-A3 and EphA3 might already occur in the retina. Therefore, the authors should provide some additional evidence for the axonal localization of the KI ephrin-a3 in the SC (e.g., Western blots, immunostainings on the SC or in-vitro assays).

My second major issue relates to the modeling. The presented model principally aids the understanding of the corticocollicular effects. In its present state, however, it has some deficiencies. First, either the key equation of the model, given in subsection "In silico replication of the duplication of the cortico-collicular map", referring to two gradients on both, the target and the field of origin is wrong, or not all gradients used are specified. Second, I can\'t see how the fitting equations given for the ephrin gradients relate to the actual measurements. And third, for modeling corticocollicular mapping, the authors arbitrarily reduce the ephrin-A5 gradient to 80%. This is neither well motivated, nor has it been evaluated, how this affects the outcome. When the mentioned issues have been clarified, I will cordially support the publication of this nice piece of work in *eLife*.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"A Molecular Mechanism for the Topographic Alignment of Convergent Neural Maps\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Andrew King as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All three reviewers agree that you and your co-authors have nicely addressed the criticisms and revised the figures, including demonstration of duplicated maps, appropriately and made other requested revisions. The reviewers reiterated that they consider this an important study for the field.

In their appraisal of the initial manuscript, the reviewers called for a demonstration of RGC-expressed ephrin A3 to support the main tenet of the study -- that RGC axon-derived ephrin A3 plays a role in shaping corticocollicular (CC) maps. For the revised manuscript, the reviewers appreciated the new data showing localization with the commercial antibody from LSBio, with good staining of RGCs and expression on axon-like profiles in the optic nerve in the proximal and middle (erroneously termed \"medial\") sectors, albeit not in the distal sector. We acknowledge that immunohistochemistry was the most expedient action to take for the demonstration of ephrin A3, even though most in the field have failed to reveal Ephs and ephrins by this method. Nonetheless, we wish to see additional revisions for the ephrin A3 expression as listed below, first and foremost, to demonstrate antibody specificity.

Essential revisions:

1\) Confirm antibody specificity by staining WT vs. ephrin-A3 KO retinal and SC tissue, if possible testing tissue from the same litter (or source/background). This would validate the results, especially for the expression in the retina and optic nerve.

2\) Include results of the expression as shown in the rebuttal in the manuscript itself, in Supplemental Data.

3\) More thoroughly address the \"dissonance\" in ephrin-A3 expression along RGC axons in the Discussion.

4\) Ephrin-A3 is present on axons, but below the detection limit; thus, there cannot be 100% transfer of the retinal ephrin-A3 into the axons. You should include this finding in your model.

10.7554/eLife.20470.029

Author response

Editors' note: the author responses to the first round of peer review follow.\]

*\[...\] Reviewer \#1: \[...\] 1) I am confused why ectopic expression of ephrin-A3 in Isl2(+) RGCs does not lower the effective concentration of EphAs in these cells. The experiments in [Figure 6](#fig6){ref-type="fig"} show that extra EphA3 can mask the ectopic ephrin-A3. So why doesn\'t the ectopic ephrin-A3 mask the available EphA, especially in the nasal half of the retina where EphA levels are graded and low? The authors address this in the Discussion \"However, we did not observe any retinocollicular mapping defects regardless of the mutant genotypes, suggesting that ephrin-A3 ectopic expression does not inactivate endogenous co-expressed EphA4/A5/A6 receptors in RGCs, although we showed specific inactivation of EphA3, suggesting distinctive interactions in cis between ephrin-A/EphA pairs as previously observed (Yin et al., 2004; Falivelli et al., 2013; Klein and Kania, 2014).\" But this explanation is somewhat unsatisfying based on the current knowledge of ephrin-A binding affinities for EphA receptors. It would be nice if the authors can address the specificity of masking more directly, perhaps by showing ectopic ephrin-A3 does not change the sensitivity of RGC axons to ephrin-A5 in trans, although I understand that this may be beyond the scope of the paper.*

Binding affinities for EphAs and ephrin-As have indeed been documented (Brambilla et al., 1995; Gale et al., 1996), but assess binding of EphA receptors and ephrin-A ligands in trans (i.e., on different cells or applied exogenously). These values do not apply here as our hypothesis suggests an interaction in CIS (on the same cell), for which binding affinities data are unavailable. Our results suggest a cis-inactivation of EphA3 and ephrin-A3 when expressed on the same RGCs, but not with endogenous retinal EphA4/A5/A6 receptors. CIS-inactivation of the EphA4/A5/A6 endogenous receptors by ectopic ephrin-A3 would affect their binding to collicular ephrin-As. In the ephrin-A3KI mutants, this would generate 2 populations of RGCs: one, the *Isl2(-)*, presenting WT EphAs binding capacity in TRANS and the other, the *Isl2(+)*, with decreased EphAs binding capacity in TRANS. In such a scenario and according to the Relative Signaling mechanism (Brown et al., 2000; Reber et al., 2004; Bevins et al., 2011) a duplicated (full or partial) retino-collicular map should be obtained, which was not observed (refer to [Figure 3A](#fig3){ref-type="fig"} of our revised version). To further support our interpretation, we characterized the retino-collicular maps in compound mutant ephrin-A3KI/KI, EphA4KO. In these mutants, decreasing the relative EphA signaling strength, by diminishing or abolishing homogeneous EphA4 retinal expression, would reveal any EphA4/A5/A6 signaling defect (a consequence of a cis-inactivation) upon collicular ephrin-As binding in TRANS. As a consequence, duplicated retino-collicular maps should be observed in the compound mutants, particularly in the caudal pole of the SC where nasal RGCs, expressing low levels of EphAs, project. However, as shown in [Author response image 1](#fig10){ref-type="fig"}, our data revealed normal retino-collicular maps in ephrin-A3KI/KI, *EphA4+/-* and ephrin-A3KI/KI, *EphA4-/-*, indicating that ectopic expression of ephrin-A3 in *Isl2(+)* RGCs does not inactivate endogenous retinal EphAs receptors.10.7554/eLife.20470.023Author response image 1.Retino-collicular projections analysis at P8 in *ephrin-A3KI/KI∷EphA4+/-* (**A**) and *ephrin-A3KI/KI∷EphA4-/-* (**B**) double mutants showing single retino-collicular maps (left panels) and examples of anterograde tracings (right panels: whole-mount confocal SCs images showing the single TZs -- white spot).Scale bars: 200 µm. R, rostral; C, caudal.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.023](10.7554/eLife.20470.023)

*2) It would be nice to directly visualize the discontinuity of ephrin-A3 expression on RGC axons in the SC using immunocytochemistry.*

The discontinuity (or alternating pattern) of ephrin-A3 expression on RGCs in the SC is generated by the homogeneous distribution of the *Isl2(+)* and *Isl2(-)* RGC TZs forming the retino- collicular map. To visualize the discontinuity of ephrin-A3 expression on RGCs axons /TZs in the SC of ephrin-A3KI/KI animals, we performed an immunohistochemical analysis, using the ephrin-A3 antibodies that clearly revealed ectopic ephrin-A3 expression in the retina (LSBio LS- C6547, [Figure 1A-F](#fig1){ref-type="fig"}). Our data show a strong ephrin-A3 staining level in collicular cells, similar between WT and ephrin-A3KI/KI littermates at P3 and P8 (in accordance with qPCR data shown [Figure 5C](#fig5){ref-type="fig"} in our revised version). However, no discontinuity in ephrin-A3 staining in the SC can be observed in ephrin-A3KI/KI. This is likely a consequence of the exceptionally high level of *endogenous* ephrin-A3 staining in collicular cells, making any additional ephrin-A3 variation on RGCs axons difficult to discern immunohistochemically.10.7554/eLife.20470.024Author response image 2.Immunohistochemical staining on P3 and P8 ephrin-A3KI/KI and WT SC parasagittal sections revealing ephrin-A3 expression in collicular cells (controls are without primary anti-ephrin-A3 antibody).Scale bars: 200 µm (A -- D), 30 µm (A' -- D', A'', B''); R, rostral; C, caudal.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.024](10.7554/eLife.20470.024)

We further analyzed ephrin-A3 expression using immunohistochemistry (amplified by streptavidin/biotin) on RGCs axons in parasagittal sections of the SC after DiI labelling of RGCs at P3 and P8. As shown in [Author response image 3](#fig12){ref-type="fig"}, DiI labelled RGC axons can be observed in the SC, as well as strong collicular ephrin-A3 staining. However, no ephrin-A3 staining on these very thin DiI- labelled RGC axons can be detected.10.7554/eLife.20470.025Author response image 3.Immunostaining revealing ephrin-A3 expression (green) in P3 and P8 ephrin- A3KI/KI and WT SC parasagittal sections after retinal anterograde DiI injection (red fibers).Scale bars: 30 µm (A, D), 10 µm (B -- F).**DOI:** [http://dx.doi.org/10.7554/eLife.20470.025](10.7554/eLife.20470.025)

We next performed ephrin-A3 immunohistochemistry on P3 ephrin-A3KI/KI and WT optic nerve longitudinal sections (proximal, medial, and distal to the optic cup) using signal amplification (streptavidin/biotin). As shown in [Author response image 4](#fig13){ref-type="fig"}, specific ephrin-A3 labeling could be detected readily on fibers within the proximal part of the optic nerve in WT and ephrin-A3KI/KI mutants, and the medial part of the optic nerve in ephrin-A3KI/KI, but was nearly impossible to discern in the distal part, suggesting that ephrin-A3 is indeed present on RGCs axons (as shown in vivo on retinal sections [Figure 1B-F](#fig1){ref-type="fig"} and in vitro [Figure 1O-Q](#fig1){ref-type="fig"}' of the revised version), but that expression becomes dispersed as these axons advance into the SC. The absence of strong staining in the distal part in ephrin-A3KI/KI and WT suggests that ephrin-A3 ligands are spread along the axons and reach a low concentration, below the detection limit of immunohistochemistry. This would explain why ephrin-A3 cannot be detected on RGC axons within the SC (see response above §2).10.7554/eLife.20470.026Author response image 4.P3 ephrin-A3KI/KI (A-C', G, G') and WT (D-F') optic nerve sections, at the proximal, medial and distal level from the optic disc, immunostained for ephrin-A3 (in green), DAPI (in blue) after retinal DiI injections (in red).A control experiment (without ephrin-A3 antibody) is shown on ephrin-A3KI/KI proximal optic nerve section. Scale bars: 20 µm (A-G'), 10 µm (high magnification panels in A', B', D', E'). Arrows in insets show ephrin-A3 positive fibers.**DOI:** [http://dx.doi.org/10.7554/eLife.20470.026](10.7554/eLife.20470.026)

*3) The duplication of the V1-SC projection is not very pronounced. It seems possible that the termination zones are just a bit blurry. Two color DiI, DiO injections in V1 would unambiguously demonstrate that the TZs are duplicated (see Triplett et al. 2009 [Figure 6](#fig6){ref-type="fig"}).*

As requested by reviewer 1, two color injections in V1 (red: DiI, cyan: DiD) were performed. As shown in [Figure 4---figure supplement 2A, B](#fig4s2){ref-type="fig"} (subsection "Cortico-collicular maps are duplicated in [Isl2-]{.ul}Efna3KI mutants", first paragraph), duplicated cortico-collicular TZs can be revealed at P15 in ephrin-A3KI/KI animals, whereas WT littermates only show single projections. Corresponding V1 injections are shown as whole-mount (white spot: DiI; dark spot: DiD).

*4) The SC s of the anterograde DiI retinal injections should be sectioned as done for the V1-SC projection. It is possible that ectopic termination zones in deeper SC lamina may not be revealed in a whole mount view.*

Analyses of the retino-collicular TZs by sagittal sectioning were originally performed at the time of the retino-collicular maps characterization. [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} (subsection "Knock-in mice for Efna3 ectopic expression in Isl2(+) RGCs show normal retino-collicular and retino-geniculate projections", last paragraph) shows examples of collicular sagittal sections after anterograde retinal labelling in WT and ephrin-A3KI/KI SCs at P8. Projections in both genotypes are similar in terms of layering, size and density of the TZs.

*Reviewer \#2: \[...\] Is there an alteration of ephrinA3 distribution in the SC of the Isl2(-) ephrin-A3KI mice? EphrinA3 IHC was performed in this manuscript, but only in retina. For the model proposed to be valid (really the crux of the manuscript) one would expect to see fluctuations in ephrin A3 distribution in SC in mutants (associated with retinal arbors). This is an essential piece of data that is missing. And it should be done on WT, single copy mutants, and double copy mutants.*

This same point was made by reviewer 1. Please see our comments and data as above. Immunohistochemistry on WT and ephrin-A3KI mutant littermates was performed (see response above, reviewer 1 §2). They revealed very strong endogenous ephrin-A3 staining in collicular cells at P3 and P8 in both eprin-A3KI/KI and WT animals. However, no alternating pattern above this staining pattern can be observed in ephrin-A3KI/KI when compared to WT littermates. As mentioned above (see response reviewer 1 §2 and Author response [images 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}), we believe this represents a signal-to-noise issue that reflects (a) the strong ephrin-A3 staining in collicular cells masking any ephrin-A3 variation on RGCs axons, and (b) the relatively low level of knock- in ephrin-A3 present on the very thin retinal axons, which is below the detection level afforded by immunohistochemistry. As outlined above, there is knock-in ephrin-A3 expression in the optic nerve that is readily detectable by immunohistochemical methods.

*The duplications of cortical maps are quite subtle in these mutants, compared to those of previous studies. In fact, they are so subtle they are difficult to discern in some cases in the manuscript -- the images in [Figure 4B](#fig4){ref-type="fig"} both look like double maps compared to WT controls. How were double maps quantified and identified? It seems critical to show the injection sites in V1 for each case (like is done for retinocollicular maps) to ensure that double maps are not the result of wider injection sites.*

To convince the reviewer that V1-SC projections are indeed duplicated in ephrin-A3KI mutants, we provide examples of pictures from sagittal sections of the SC after V1 DiI labelling in both ephrin-A3KI/KI and ephrin-A3KI/+ mutants as well as WT littermates. Thresholding using ImageJ was performed with the same parameters for all 3 genotypes and revealed single and duplicated cortico-collicular TZs in ephrin-A3 mutants and only single TZs in WT littermates.

These figures were added to our revised version, [Figure 4---figure supplement 1A-C](#fig4s1){ref-type="fig"} and subsection "Cortico-collicular maps are duplicated in *Isl2(-)* Efna3KI mutants", first paragraph. We also added whole-mount pictures of the V1 injections corresponding to the duplicated and single cortico-collicular TZs shown in our revised version of [Figure 4](#fig4){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} legend.

*Likewise, an important part of the manuscript was that retinal maps are unaffected. But the analysis of those maps seems less detailed than the cortical maps. Perhaps subtle changes in retinal maps would be observed if sections of SC were analyzed at high magnification, rather than surface images. Again, consistency in analysis methods for both sets of maps and data is important for the conclusions of the manuscript.*

Detailed analysis of retino-collicular TZs in ephrin-A3KI/KI mutants have been performed using sagittal section of the SC and confocal microscopy (see response to reviewer 1 §4 and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} and subsection "subsection "Knock-in mice for Efna3 ectopic expression in Isl2(+) RGCs show normal retino-collicular and retino-geniculate projections", last paragraph") and revealed no major differences (in size and layering of the TZs) compared to WT littermates.

*While the inactivation of ephrinA3 overexpression by co-expression of EphA3 was viewed as a strengt, of the manuscript, some of the data demonstrating the validity of this approach was dumped into the supplemental material. It seems too important to be \"supplemental\" as it is a critical component of this manuscript. Likewise more data needs to be presented to convince this reviewer that this result is not the result of the lack of penetrance in single copy of EphA3 mutant, since it has been previously reported that duplicated maps are observed in only some single copy mutants.*

The lack of penetrance in the EphA3KI/+ mutants the reviewer is mentioning refers to recent data published by Owens et al., 2015, showing a single retino-collicular map in 25% of the EphA3KI/+ mutants, which is somewhat controversial. Previous, more precise, and detailed anatomical analyses of the retino-collicular map in the EphA3 single copy mutants showed consistent (in 100% of the EphA3KI/+ mutants) duplications (originally by Brown et al., 2000 and further demonstrated by Reber et al., 2004). In particular, projections from nasal RGCs to the caudal pole of the SC *ALWAYS* produced duplicated TZs as shown in Brown et al., 2000; Reber et al., 2004 and in the revised version ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

*In addition to major concerns described above, there are also concerns in the presentation of the manuscript:*

*1) In some cases, images appear to be poorly selected to make the authors point. For example see [Figure 2A, B](#fig2){ref-type="fig"} which are described as being similar but are not of equal quality. Other examples include 3H-K, [Figure 4](#fig4){ref-type="fig"}, and [Figure 6D, E](#fig6){ref-type="fig"}.*

We have added new images for [Figure 2A, B](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} (single TZ panel in ephrin-A3KI/+). Panel 3 from [Figure 6D](#fig6){ref-type="fig"} was also changed for one of higher quality.

*2) In several cases proper labeling is missing or inappropriate on the figures. In [Figure 1G, H](#fig1){ref-type="fig"} labels are missing. In [Figure 3N-O](#fig3){ref-type="fig"} what are the arrows? (And the figures in [Figure 3L-O](#fig3){ref-type="fig"} are insufficient to claim normal eye-specific segregation in this mutant). It's unclear what [Figure 5B](#fig5){ref-type="fig"} is amplifying? (And if its ephrinA3 why isn\'t it in WT retina?). More care should be paid to all figures and legends.*

Missing labels specifying the ganglion cell layer (GCL) are now presented in the revised version [Figure 1G, H](#fig1){ref-type="fig"}.

Additional data obtained from the eye-specific segregation analyses are presented in [Figure 3](#fig3){ref-type="fig"} of our revised version.

[Figure 5B](#fig5){ref-type="fig"} correspond to an amplicon of 90 bp located within the IRES sequence of the targeted Isl2 locus. This IRES sequence is present in the bi-cistronic RNA transcribed from the targeted Isl2 locus and is therefore present only in Isl2(+) RGCs in ephrin-A3KI/KI but not in SC or V1 nor in WT littermates (see [Figure 5B](#fig5){ref-type="fig"} legend).

*Reviewer \#3:*

*The formation of topographic axonal maps is a key element of brain wiring. Visuotopic mapping is mainly instructed by the ephrin/Eph system, enabling forward, reverse, axon/target, axon/axon and cis signals. The actual contribution of each of these signals and their integration, has remained highly controversial. The authors specifically address the role of axonally located ephrin-As by a knock-in (ki) of ephrin-A3 into a random half-population of retinal ganglion cells (RGCs). Therefore, their paper is of major importance to the field. Their approach is valid, the experiments are thoroughly performed, carefully evaluated and lucidly presented in the paper. I have, however, two (somewhat) major issues that should be clarified before publication.*

*Based on our current understanding, a duplicated retinocollicular map in the KI/KI animals would be expected. Ki axons should grow to the posterior superior colliculus (SC) due to axon/target reverse signaling (Rashid T., et al. 2005). Wildtype axons should be anteriorly displaced due to axon/axon forward signaling (Suetterin P., et al., 2015). Intriguingly, the retinocollicular map is unaffected by the ki. In contrast, however, the V1-corticocollicular map is split up, notably indicating a role of ephrin-A3 on retinal axons in the chemotopic guidance of V1 cortical axons. The same projection has previously been claimed to be aligned by activity-dependent mechanisms (Triplett J., et al., 2009).*

Activity-dependent mechanisms have indeed been shown to align cortico-collicular mapping (Triplett et al., 2009), as mentioned by the reviewer. We suggest, as shown already for retino-collicular projections, that the mechanisms of cortico-collicular map alignment include *both* EphA/ephrin-A guidance cues *and* correlated activity (see subsection "Retinal EFNA3 in cortico-collicular mapping", last paragraph).

*Although being very exciting, the new results are to some degree in conflict with previous observations, necessitating thorough control. Thus, I\'m still not fully convinced, that an amount of KI ephrin-A3 arrives in the SC that could be functionally relevant to retinocollicular mapping. Maybe the pioneering retinocollicular mapping is more robust to changes than the following corticocollicular map. Immunostainings of isolated kiRGCs display labeling on the neurites ([Figure 1O, O](#fig1){ref-type="fig"}\'), but this is after 6 DIV and it remains unclear whether the shown neurites are axons or dendrites. The authors show that concomitant KI of EphA3 rescues the mapping effects of both knock-ins, but the mutual neutralization of ephrin-A3 and EphA3 might already occur in the retina. Therefore, the authors should provide some additional evidence for the axonal localization of the KI ephrin-a3 in the SC (e.g., Western blots, immunostainings on the SC or in-vitro assays).*

We chose to address the reviewer's point by ephrin-A3 immunohistochemistry in WT and ephrin-A3KI mutant SCs (see response above, reviewer 1 §2).

As requested by the reviewer, we performed double-labelling of RGCs in vitro using ephrin-A3 and Tau (axonal marker) antibodies (see revised version [Figure 1O-Q](#fig1){ref-type="fig"}'), showing co-localization of both ephrin-A3 and Tau and suggesting the expression of ephrin-A3 on RGC axons in vitro (subsection "Knock-in mice for Efna3 ectopic expression in Isl2(+) RGCs show normal retino-collicular and 78 retino-geniculate projections", first paragraph and [Figure 1](#fig1){ref-type="fig"} legend).

Moreover, previous work in the laboratory demonstrated that the culture conditions used here do not allow the formation of RGC dendrites in vitro (see Steinmetz et al., 2006).

*My second major issue relates to the modeling. The presented model principally aids the understanding of the corticocollicular effects. In its present state, however, it has some deficiencies. First, either the key equation of the model, given in subsection "In silico replication of the duplication of the cortico-collicular map", referring to two gradients on both, the target and the field of origin is wrong, or not all gradients used are specified.*

We used the equations of the model as described by Koulakov and Tsignakov, 2004. The key equation described refers to ONE EphA receptors gradient (R~A~) and its value at two locations in the retina/V1 (i and r') and ONE ephrin-A ligands gradient (LA) and its value at two locations in the SC (i and r'), which is indeed confusing. In our revised version, the two locations in the retina/V1 are (i) and (j) and in the SC are (i') and (j') (see subsection "In silico replication of the duplication of the cortico-collicular map").

*Second, I can\'t see how the fitting equations given for the ephrin gradients relate to the actual measurements.*

We thank the reviewer for pointing out our mistake (mis-copy). The equations indeed do not relate to the actual measurements of [Figure 7](#fig7){ref-type="fig"}. The equations computed in our model correspond to the retinal ephrin-As gradient transposed in the SC: during the retino-collicular projections, the x axis in the retina \[nasal (0) -- temporal (100)\] is flipped onto the rostral (0) -- caudal (100) axis in the SC where nasal RGCs project caudally and temporal RGCs project rostrally. We corrected the equations (subsection "In silico modelling and theoretical analysis of cortico-collicular map alignment") and made this point clearer in our revised version.

*And third, for modeling corticocollicular mapping, the authors arbitrarily reduce the ephrin-A5 gradient to 80%. This is neither well motivated, nor has it been evaluated, how this affects the outcome.*

Different simulations were performed using proportion of retinal ephrin-A5 ranging from 0% to 100% (see table below). The 3-step model simulates the cortico-collicular map duplications observed experimentally in ephrin-A3KI mutants at 80% of retinal ephrin-A5 and higher (in bold blue in the table). Consistent with the literature showing a role of retinal

ephrin-A5 in RGCs fiber-fiber interactions (Suetterlin and Drescher, 2014), we chose to retain 80% of retinal ephrin-A5 in the simulations.

\% CC duplication ( ± 95CI)% ephrin-A5ephrin-A3KI/+ephrinA3KI/KI5058 ( ± 2)64 ( ± 1.2)6052 ( ± 2.5)63 ( ± 1.7)7049 ( ± 1.7)52 ( ± 1.7)8041 ( ± 2.4)46 ( ± 1.2)9040 ( ± 2.5)48 ( ± 2.2)10041 ( ± 2.6)49 ( ± 2)experimental4347

\[Editors' note: the author responses to the re-review follow.\]

*Essential revisions:*

*1) Confirm antibody specificity by staining WT vs. ephrin-A3 KO retinal and SC tissue, if possible testing tissue from the same litter (or source/background). This would validate the results, especially for the expression in the retina and optic nerve.*

As requested, we confirmed that both of our antibodies used to detect EFNA3 (Ab LSBio ref\# LSC6547 and Ab Invitrogen ref\# 36-7500) are specific by comparing the staining observed on P8 EfnA3-/- (n = 4 animals) versus P8 Efna3+/- (n = 2 animals) retina, optic nerve and SC sections (obtained from Efna3+/- and Efna3-/- heads kindly provided by Dr. D. Feldheim, UC Santa Cruz). As shown below, both antibodies show no specific staining in Efna3-/- sections, validating their specificity.10.7554/eLife.20470.027Author response image 5.Immunohistochemistry on P8 Efna3-/- (A, B, C, G, H, I) and Efna3+/- (D, E, F, J, K, L) tissue sections using EFNA3 antibodies from LSBio (LSC6547) (A-F) and Invitrogen (36-7500) (G-L).Scale bars, 100µm (A, C, D, F, G, I, J, L), 50 µm (B, E, H, K).**DOI:** [http://dx.doi.org/10.7554/eLife.20470.027](10.7554/eLife.20470.027)

Figures B and C have been added to the main manuscript, [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"} and [Figure 4---figure supplement 4H](#fig4s4){ref-type="fig"} (subsection "Cortico-collicular maps are duplicated in *Isl2(-)* Efna3KI mutants", last paragraph) respectively.

*2) Include results of the expression as shown in the rebuttal in the manuscript itself, in Supplemental Data.*

As requested, these expression data now appear in the third version of our manuscript as [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}, and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} (legends and related text in subsection "Cortico-collicular maps are duplicated in Isl2-Efna3KI mutants", last paragraph).

*3) More thoroughly address the \"dissonance\" in ephrin-A3 expression along RGC axons in the Discussion.*

This point has been discussed in our third version of the manuscript, in the last paragraph of the subsection "Retinal EFNA3 in cortico-collicular mapping".

*4) Ephrin-A3 is present on axons, but below the detection limit; thus, there cannot be 100% transfer of the retinal ephrin-A3 into the axons. You should include this finding in your model.*

As mentioned by reviewer 3, axonal ephrin-A3 expression (in the distal part of the optic nerve as well as in the SC only) is below our immunohistochemical detection limit, most likely because of dissolution of ephrin-A3 along the axons. This dissolution is very likely to occur for all EphA receptor and ephrin-A ligands in this system (see Dutting et al., 1999; Triplett et al., 2009, Supplementary [Figure 4](#fig4){ref-type="fig"}). Therefore, if we reduce transfer, we should do it for all guidance cues, not just retinal ephrin-A3. However, given that we have no plausible way of setting realistic values for all these dissolution rates, we believe any adjustments would be too speculative and under-constrained to be useful.
